Advanced search
Start date

Development of vaccine anti-SARS-CoV-2 based on VLPs

Grant number: 20/09404-0
Support Opportunities:Scholarships in Brazil - Post-Doctoral
Effective date (Start): September 01, 2020
Effective date (End): April 30, 2023
Field of knowledge:Biological Sciences - Immunology - Applied Immunology
Principal Investigator:Gustavo Cabral de Miranda
Grantee:Larissa Vuitika
Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil
Associated research grant:20/05146-7 - Development of vaccine anti-SARS-CoV-2 based on VLPs, AP.R


The emerging SARS-CoV-2 virus appeared in China and easily spread around the world with a tremendous lethality. In less than three months of its identification, it has already caused more than 30,000 deaths worldwide with an increasing number of fatalities. As it is a new virus introduced into the human population, therefore there is no prior immunity; it has easy spread and lethality varies from 1 to 16% according to country, age group and comorbidities. In the absence of a specific vaccine or treatment, the pandemic is paralyzing entire continents. In this project, we aim to use the vaccine platform based on VLPs (Virus-Like Particles) conjugating peptide sequences from SARS-CoV-2 to Q²VLPs andVP1VLPs. The choosen antigen is the Spike protein from the SARS-CoV-2, and make this VLPs as an antigen delivering to the components of the immune system cells. It is worth to mention that this project was quickly adapted for the development of an effective and safe vaccine against SARS-CoV2 to the JP project, process number: 2019/14526-0. Because of this, we are already working on selecting the best antigens to be combined with VLPs due to the enormous urgency that this historic moment demands of us. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list using this form.